Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial.

ABSTRACT:

Background

Impulse control disorders (ICDs) are frequently encountered in Parkinson's disease (PD).

Objectives

We aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs.

Methods

We conducted a multicentre trial in five movement disorder departments. Patients with PD and ICDs (n = 41) were enrolled in an 8-week, randomised (1:1), double-blind, placebo-controlled study of clonidine (75 μg twice a day). Randomisation and allocation to the trial group were carried out by a central computer system. The primary outcome was the change at 8 weeks in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) score. A reduction of the most elevated subscore of the QUIP-RS of more th

SUBMITTER: Laurencin C 

PROVIDER: S-EPMC10511565 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature